CAR T-Cell Therapy

James Ignatz-Hoover, MD, PhD, discusses the evolving use of CAR T-cell therapies and bispecific antibodies in multiple myeloma.

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.

Sattva S. Neelapu, MD, discusses the optimal processes of CAR T-cell therapy administration and the remaining unmet needs in the space.

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

Samuel Yamshon, MD, of Weill Cornell Medicine/NewYork-Presbyterian, discusses strategies to improve CAR T-cell durability in patients with non-Hodgkin lymphoma.

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

James Ignatz-Hoover, MD, PhD discusses sequencing CAR T cell therapies and bispecific agents in treating pretreated patients with multiple myeloma.

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Olalekan O. Oluwole, MBBS, MD, discusses the feasibility of using CAR T-cell therapy in patients with nonhematologic autoimmune disorders.

Samer A. Srour, MB ChB, MS, explains the significance of early safety and efficacy data with CTX130 in CD70-expressing clear cell renal cell carcinoma.

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of cilta-cel in relapsed/refractory multiple myeloma.

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.

Francesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.

The FDA has approved cilta-cel for select patients with relapsed/refractory multiple myeloma who have received at least 1 line of therapy, and who are lenalidomide refractory.

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Jay Spiegel, MD, discusses some of the challenges of using CAR T-cell therapy in patients with solid tumors.